Vividion Therapeutics

Executive Summary

Vividion Therapeutics is a private biotechnology company based in San Diego, leveraging a proprietary chemoproteomics platform to discover small molecule therapeutics against previously undruggable disease targets. Founded in 2013, the company integrates covalent chemistry with proteome-wide screening to identify novel binding sites on proteins, expanding the druggable proteome. Its pipeline focuses on oncology and immunological diseases, aiming to transform patient care by addressing high-value targets that have eluded traditional drug discovery. The platform's ability to systematically map ligandable hotspots across the proteome provides a competitive advantage in generating first-in-class molecules.

Upcoming Catalysts (preview)

• TBDInitial Phase 1 clinical data readout for lead candidate40% success
• TBDAnnouncement of new partnership or licensing deal for platform60% success
• TBDDisclosure of preclinical data for a novel program at a major conference70% success